Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cochlear ( (AU:COH) ) just unveiled an update.
Cochlear Limited has announced the Nucleus Nexa System, a groundbreaking cochlear implant system featuring upgradeable firmware, which allows users to access future innovations seamlessly. The Nucleus 8 Nexa Sound Processor, noted for being the smallest and lightest with an all-day battery life, enhances patient convenience by securely storing hearing settings on the implant, reducing the need for clinic visits.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
More about Cochlear
Cochlear Limited operates in the medical device industry, specializing in cochlear implants and sound processors. The company focuses on innovations that enhance hearing experiences for individuals with hearing impairments.
Average Trading Volume: 173,116
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$20.4B
Learn more about COH stock on TipRanks’ Stock Analysis page.